Bristol-Myers Gets FDA Priority Review for Lisocabtagene Maraleucel in Large B-Cell Lymphoma
February 13 2020 - 8:04AM
Dow Jones News
By Colin Kellaher
Bristol-Myers Squibb Co. on Thursday said the U.S. Food and Drug
Administration accepted for priority review its biologics license
application for its lisocabtagene maraleucel immunotherapy in
certain forms of large B-cell lymphoma.
The New York biopharmaceutical company said the application
covers lisocabtagene maraleucel for the treatment of adults with
relapsed or refractory large B-cell lymphoma after at least two
prior therapies.
The FDA grants priority review to medicines that have the
potential to provide significant improvements in the treatment of a
serious disease, and the designation shortens the review period to
six months from the standard 10 months.
Bristol-Myers said the agency set a target action date of Aug.
17 for the application.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 13, 2020 07:49 ET (12:49 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Apr 2023 to Apr 2024
